Stem definition | Drug id | CAS RN |
---|---|---|
beta3-adrenoreceptor agonists | 4382 | 223673-61-8 |
Dose | Unit | Route |
---|---|---|
50 | mg | O |
Property | Value | Reference |
---|---|---|
Vd (Volume of distribution) | 23.80 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 13.60 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.29 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 50 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
June 28, 2012 | FDA | APGDI |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Urinary retention | 160.75 | 13.12 | 104 | 17108 | 26086 | 50561826 |
Intentional product misuse | 138.79 | 13.12 | 120 | 17092 | 46614 | 50541298 |
Blood pressure increased | 129.82 | 13.12 | 191 | 17021 | 132941 | 50454971 |
Urinary tract infection | 125.32 | 13.12 | 251 | 16961 | 223769 | 50364143 |
Blepharospasm | 79.85 | 13.12 | 32 | 17180 | 2916 | 50584996 |
Urinary incontinence | 78.81 | 13.12 | 70 | 17142 | 28138 | 50559774 |
Fall | 77.63 | 13.12 | 270 | 16942 | 334662 | 50253250 |
Memory impairment | 70.33 | 13.12 | 109 | 17103 | 79251 | 50508661 |
Hypertension | 68.03 | 13.12 | 191 | 17021 | 211012 | 50376900 |
Taste disorder | 63.55 | 13.12 | 38 | 17174 | 8286 | 50579626 |
Drug dispensed to wrong patient | 61.00 | 13.12 | 14 | 17198 | 181 | 50587731 |
Toxicity to various agents | 59.87 | 13.12 | 3 | 17209 | 212496 | 50375416 |
Residual urine volume increased | 58.56 | 13.12 | 10 | 17202 | 21 | 50587891 |
Dry mouth | 55.21 | 13.12 | 81 | 17131 | 56097 | 50531815 |
Bladder pain | 48.34 | 13.12 | 19 | 17193 | 1645 | 50586267 |
Multiple sclerosis relapse | 48.20 | 13.12 | 66 | 17146 | 42898 | 50545014 |
Multiple sclerosis | 47.82 | 13.12 | 46 | 17166 | 20447 | 50567465 |
Off label use | 44.26 | 13.12 | 294 | 16918 | 474132 | 50113780 |
Dermatitis atopic | 42.87 | 13.12 | 22 | 17190 | 3564 | 50584348 |
Kidney infection | 39.86 | 13.12 | 40 | 17172 | 18706 | 50569206 |
Contraindicated product administered | 39.25 | 13.12 | 3 | 17209 | 148955 | 50438957 |
Scleral discolouration | 38.54 | 13.12 | 11 | 17201 | 351 | 50587561 |
Maternal exposure during pregnancy | 37.49 | 13.12 | 5 | 17207 | 159773 | 50428139 |
Epilepsy | 36.92 | 13.12 | 41 | 17171 | 21526 | 50566386 |
Cystitis | 36.40 | 13.12 | 59 | 17153 | 44505 | 50543407 |
Pollakiuria | 33.57 | 13.12 | 41 | 17171 | 23810 | 50564102 |
Palpitations | 32.86 | 13.12 | 88 | 17124 | 94418 | 50493494 |
Muscular weakness | 32.56 | 13.12 | 88 | 17124 | 94925 | 50492987 |
Anxiety disorder | 31.28 | 13.12 | 18 | 17194 | 3655 | 50584257 |
Treatment failure | 30.68 | 13.12 | 5 | 17207 | 137632 | 50450280 |
Sinonasal obstruction | 30.41 | 13.12 | 8 | 17204 | 187 | 50587725 |
On and off phenomenon | 30.36 | 13.12 | 13 | 17199 | 1399 | 50586513 |
Migraine | 29.15 | 13.12 | 73 | 17139 | 75207 | 50512705 |
Lip disorder | 28.82 | 13.12 | 12 | 17200 | 1205 | 50586707 |
Infusion related reaction | 28.51 | 13.12 | 11 | 17201 | 169546 | 50418366 |
Rheumatoid arthritis | 28.18 | 13.12 | 17 | 17195 | 202533 | 50385379 |
Micturition urgency | 28.17 | 13.12 | 23 | 17189 | 8241 | 50579671 |
Vitamin D deficiency | 27.36 | 13.12 | 26 | 17186 | 11376 | 50576536 |
Dementia | 26.68 | 13.12 | 30 | 17182 | 15967 | 50571945 |
Glossodynia | 26.20 | 13.12 | 4 | 17208 | 115565 | 50472347 |
Schizophrenia | 26.09 | 13.12 | 21 | 17191 | 7376 | 50580536 |
Exposure during pregnancy | 25.66 | 13.12 | 5 | 17207 | 121010 | 50466902 |
Therapeutic product effect decreased | 24.28 | 13.12 | 8 | 17204 | 136042 | 50451870 |
Gait disturbance | 24.11 | 13.12 | 108 | 17104 | 149897 | 50438015 |
Intercepted medication error | 24 | 13.12 | 8 | 17204 | 431 | 50587481 |
Feeling drunk | 23.61 | 13.12 | 15 | 17197 | 3638 | 50584274 |
Idiopathic orbital inflammation | 23.55 | 13.12 | 6 | 17206 | 123 | 50587789 |
Nocturia | 23.51 | 13.12 | 19 | 17193 | 6711 | 50581201 |
Anal incontinence | 23.48 | 13.12 | 24 | 17188 | 11466 | 50576446 |
Sputum retention | 23.32 | 13.12 | 8 | 17204 | 471 | 50587441 |
Antineutrophil cytoplasmic antibody increased | 22.78 | 13.12 | 5 | 17207 | 52 | 50587860 |
Haemorrhoids | 22.47 | 13.12 | 30 | 17182 | 19023 | 50568889 |
Dysuria | 22.27 | 13.12 | 37 | 17175 | 28467 | 50559445 |
Systemic lupus erythematosus | 22.22 | 13.12 | 10 | 17202 | 140612 | 50447300 |
Balance disorder | 21.83 | 13.12 | 63 | 17149 | 70527 | 50517385 |
Dizziness | 21.76 | 13.12 | 196 | 17016 | 346173 | 50241739 |
Bladder disorder | 21.62 | 13.12 | 19 | 17193 | 7524 | 50580388 |
Hand deformity | 21.54 | 13.12 | 4 | 17208 | 100195 | 50487717 |
Drug hypersensitivity | 21.09 | 13.12 | 33 | 17179 | 250977 | 50336935 |
Dyspepsia | 20.89 | 13.12 | 64 | 17148 | 74033 | 50513879 |
Synovitis | 20.87 | 13.12 | 8 | 17204 | 123857 | 50464055 |
Metastatic neoplasm | 20.81 | 13.12 | 14 | 17198 | 3740 | 50584172 |
Swelling | 20.34 | 13.12 | 23 | 17189 | 200849 | 50387063 |
Constipation | 20.27 | 13.12 | 120 | 17092 | 185588 | 50402324 |
Disease progression | 20.24 | 13.12 | 4 | 17208 | 95862 | 50492050 |
Arrhythmia | 19.48 | 13.12 | 38 | 17174 | 33094 | 50554818 |
Lung neoplasm malignant | 19.22 | 13.12 | 25 | 17187 | 15459 | 50572453 |
Hypertensive crisis | 19.14 | 13.12 | 23 | 17189 | 13131 | 50574781 |
Vascular stenosis | 19.11 | 13.12 | 6 | 17206 | 267 | 50587645 |
Pharyngeal mass | 19.08 | 13.12 | 6 | 17206 | 268 | 50587644 |
Dyskinesia | 18.93 | 13.12 | 34 | 17178 | 27827 | 50560085 |
Urinary tract disorder | 18.51 | 13.12 | 11 | 17201 | 2369 | 50585543 |
Hypoaesthesia | 18.50 | 13.12 | 89 | 17123 | 127168 | 50460744 |
Conjunctival discolouration | 18.28 | 13.12 | 4 | 17208 | 41 | 50587871 |
Paraesthesia | 18.14 | 13.12 | 85 | 17127 | 120158 | 50467754 |
Lip swelling | 17.86 | 13.12 | 31 | 17181 | 24705 | 50563207 |
Product blister packaging issue | 17.69 | 13.12 | 5 | 17207 | 154 | 50587758 |
Neutropenia | 17.21 | 13.12 | 15 | 17197 | 147950 | 50439962 |
Insomnia | 17.19 | 13.12 | 110 | 17102 | 174755 | 50413157 |
Hypothyroidism | 16.37 | 13.12 | 36 | 17176 | 34089 | 50553823 |
Hyperventilation | 16.26 | 13.12 | 14 | 17198 | 5395 | 50582517 |
Thrombocytopenia | 16.02 | 13.12 | 12 | 17200 | 127661 | 50460251 |
Persistent genital arousal disorder | 15.42 | 13.12 | 5 | 17207 | 247 | 50587665 |
Muscle atrophy | 14.77 | 13.12 | 14 | 17198 | 6107 | 50581805 |
Wound | 14.53 | 13.12 | 9 | 17203 | 105785 | 50482127 |
VIIth nerve injury | 14.38 | 13.12 | 4 | 17208 | 116 | 50587796 |
Abdominal pain upper | 14.31 | 13.12 | 98 | 17114 | 159211 | 50428701 |
Neurogenic bladder | 14.29 | 13.12 | 10 | 17202 | 2847 | 50585065 |
Open fracture | 14.19 | 13.12 | 5 | 17207 | 319 | 50587593 |
Angina pectoris | 14.15 | 13.12 | 29 | 17183 | 26159 | 50561753 |
Lymphocyte count decreased | 14.06 | 13.12 | 29 | 17183 | 26278 | 50561634 |
Hyperlipidaemia | 14.06 | 13.12 | 23 | 17189 | 17467 | 50570445 |
Product packaging quantity issue | 14 | 13.12 | 7 | 17205 | 1073 | 50586839 |
Arthropathy | 13.98 | 13.12 | 20 | 17192 | 157886 | 50430026 |
Catheter site injury | 13.97 | 13.12 | 4 | 17208 | 129 | 50587783 |
Febrile neutropenia | 13.85 | 13.12 | 8 | 17204 | 97659 | 50490253 |
Discomfort | 13.84 | 13.12 | 10 | 17202 | 108370 | 50479542 |
Sleep apnoea syndrome | 13.58 | 13.12 | 27 | 17185 | 23841 | 50564071 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Urinary retention | 162.14 | 17.18 | 101 | 7440 | 31797 | 29535189 |
Hallucination | 124.73 | 17.18 | 98 | 7443 | 44614 | 29522372 |
Intentional product misuse | 63.93 | 17.18 | 60 | 7481 | 34601 | 29532385 |
Fall | 54.13 | 17.18 | 131 | 7410 | 177047 | 29389939 |
Nocturia | 46.28 | 17.18 | 28 | 7513 | 8334 | 29558652 |
Platypnoea | 45.33 | 17.18 | 8 | 7533 | 32 | 29566954 |
Confusional state | 44.98 | 17.18 | 100 | 7441 | 127777 | 29439209 |
Urinary tract infection | 43.32 | 17.18 | 71 | 7470 | 72283 | 29494703 |
Phaeochromocytoma malignant | 39.80 | 17.18 | 8 | 7533 | 72 | 29566914 |
Delusion | 38.78 | 17.18 | 28 | 7513 | 11188 | 29555798 |
Blood pressure increased | 37.05 | 17.18 | 67 | 7474 | 73736 | 29493250 |
Micturition urgency | 35.72 | 17.18 | 20 | 7521 | 5153 | 29561833 |
Urinary incontinence | 35.20 | 17.18 | 31 | 7510 | 16450 | 29550536 |
Drug ineffective | 31.41 | 17.18 | 178 | 7363 | 362992 | 29203994 |
Dementia | 29.13 | 17.18 | 24 | 7517 | 11634 | 29555352 |
Arrhythmia | 27.78 | 17.18 | 37 | 7504 | 31276 | 29535710 |
Gait disturbance | 26.45 | 17.18 | 58 | 7483 | 73291 | 29493695 |
Bone marrow oedema | 25.29 | 17.18 | 8 | 7533 | 489 | 29566497 |
Blood pressure systolic increased | 25.14 | 17.18 | 26 | 7515 | 16819 | 29550167 |
Oesophageal dilatation | 24.58 | 17.18 | 6 | 7535 | 139 | 29566847 |
Spinal cord haemorrhage | 24.29 | 17.18 | 7 | 7534 | 311 | 29566675 |
Hypertensive crisis | 23.56 | 17.18 | 18 | 7523 | 7830 | 29559156 |
Constipation | 23.36 | 17.18 | 73 | 7468 | 114087 | 29452899 |
Pollakiuria | 23.27 | 17.18 | 25 | 7516 | 16891 | 29550095 |
Extradural haematoma | 22.45 | 17.18 | 9 | 7532 | 1097 | 29565889 |
Prescribed underdose | 21.51 | 17.18 | 17 | 7524 | 7769 | 29559217 |
Off label use | 21.21 | 17.18 | 140 | 7401 | 300660 | 29266326 |
On and off phenomenon | 20.62 | 17.18 | 10 | 7531 | 1918 | 29565068 |
Orthostatic hypotension | 20.47 | 17.18 | 27 | 7514 | 22602 | 29544384 |
Dropped head syndrome | 19.82 | 17.18 | 5 | 7536 | 133 | 29566853 |
Toxicity to various agents | 19.48 | 17.18 | 10 | 7531 | 173651 | 29393335 |
Dysuria | 19.11 | 17.18 | 26 | 7515 | 22414 | 29544572 |
Cystitis interstitial | 19.09 | 17.18 | 5 | 7536 | 155 | 29566831 |
Dyskinesia oesophageal | 18.49 | 17.18 | 4 | 7537 | 53 | 29566933 |
Perineal pain | 18.11 | 17.18 | 7 | 7534 | 775 | 29566211 |
Cerebral infarction | 17.21 | 17.18 | 26 | 7515 | 24649 | 29542337 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Urinary retention | 181.37 | 13.14 | 138 | 19890 | 49063 | 64429641 |
Urinary tract infection | 125.52 | 13.14 | 243 | 19785 | 231353 | 64247351 |
Fall | 113.11 | 13.14 | 334 | 19694 | 416492 | 64062212 |
Urinary incontinence | 88.45 | 13.14 | 80 | 19948 | 36071 | 64442633 |
Blood pressure increased | 73.35 | 13.14 | 164 | 19864 | 172388 | 64306316 |
Hallucination | 72.96 | 13.14 | 101 | 19927 | 72687 | 64406017 |
Toxicity to various agents | 72.03 | 13.14 | 13 | 20015 | 363500 | 64115204 |
Blepharospasm | 68.36 | 13.14 | 29 | 19999 | 3346 | 64475358 |
Memory impairment | 63.17 | 13.14 | 103 | 19925 | 85579 | 64393125 |
Taste disorder | 62.35 | 13.14 | 38 | 19990 | 9395 | 64469309 |
Bladder pain | 55.94 | 13.14 | 21 | 20007 | 1760 | 64476944 |
Residual urine volume increased | 54.51 | 13.14 | 9 | 20019 | 16 | 64478688 |
Hypertension | 53.96 | 13.14 | 190 | 19838 | 259071 | 64219633 |
Drug dispensed to wrong patient | 53.10 | 13.14 | 14 | 20014 | 363 | 64478341 |
Intentional product misuse | 49.39 | 13.14 | 84 | 19944 | 72211 | 64406493 |
Gait disturbance | 47.47 | 13.14 | 139 | 19889 | 172016 | 64306688 |
On and off phenomenon | 45.62 | 13.14 | 20 | 20008 | 2499 | 64476205 |
Cystitis | 43.92 | 13.14 | 60 | 19968 | 42615 | 64436089 |
Platypnoea | 43.76 | 13.14 | 8 | 20020 | 32 | 64478672 |
Pollakiuria | 43.00 | 13.14 | 51 | 19977 | 31479 | 64447225 |
Micturition urgency | 42.47 | 13.14 | 31 | 19997 | 10328 | 64468376 |
Dry mouth | 42.32 | 13.14 | 71 | 19957 | 60347 | 64418357 |
Multiple sclerosis relapse | 41.08 | 13.14 | 57 | 19971 | 41078 | 64437626 |
Kidney infection | 40.75 | 13.14 | 38 | 19990 | 17800 | 64460904 |
Phaeochromocytoma malignant | 38.22 | 13.14 | 8 | 20020 | 72 | 64478632 |
Confusional state | 36.39 | 13.14 | 169 | 19859 | 260975 | 64217729 |
Muscular weakness | 36.22 | 13.14 | 104 | 19924 | 127234 | 64351470 |
Dysuria | 35.75 | 13.14 | 54 | 19974 | 42003 | 64436701 |
Migraine | 34.11 | 13.14 | 66 | 19962 | 62611 | 64416093 |
Nocturia | 33.97 | 13.14 | 28 | 20000 | 11137 | 64467567 |
Arrhythmia | 31.61 | 13.14 | 58 | 19970 | 52886 | 64425818 |
Scleral discolouration | 31.20 | 13.14 | 10 | 20018 | 522 | 64478182 |
Dementia | 30.67 | 13.14 | 35 | 19993 | 20731 | 64457973 |
Multiple sclerosis | 29.82 | 13.14 | 33 | 19995 | 18908 | 64459796 |
Delusion | 29.42 | 13.14 | 32 | 19996 | 17982 | 64460722 |
Palpitations | 28.42 | 13.14 | 84 | 19944 | 104404 | 64374300 |
Prescribed underdose | 27.69 | 13.14 | 31 | 19997 | 17984 | 64460720 |
Dizziness | 27.17 | 13.14 | 227 | 19801 | 429936 | 64048768 |
Sinonasal obstruction | 26.39 | 13.14 | 7 | 20021 | 186 | 64478518 |
Lip disorder | 26.09 | 13.14 | 11 | 20017 | 1250 | 64477454 |
Constipation | 25.97 | 13.14 | 140 | 19888 | 229197 | 64249507 |
Thrombocytopenia | 25.92 | 13.14 | 19 | 20009 | 223782 | 64254922 |
Hypertensive crisis | 25.68 | 13.14 | 30 | 19998 | 18218 | 64460486 |
Orthostatic hypotension | 23.96 | 13.14 | 48 | 19980 | 46690 | 64432014 |
Hypoaesthesia | 23.93 | 13.14 | 96 | 19932 | 139012 | 64339692 |
Balance disorder | 23.32 | 13.14 | 68 | 19960 | 83858 | 64394846 |
Idiopathic orbital inflammation | 23.28 | 13.14 | 6 | 20022 | 142 | 64478562 |
Feeling drunk | 23.05 | 13.14 | 15 | 20013 | 4152 | 64474552 |
Epilepsy | 22.94 | 13.14 | 39 | 19989 | 33492 | 64445212 |
Dyskinesia oesophageal | 22.66 | 13.14 | 5 | 20023 | 59 | 64478645 |
Cystitis interstitial | 20.54 | 13.14 | 9 | 20019 | 1123 | 64477581 |
Infusion related reaction | 20.32 | 13.14 | 13 | 20015 | 164454 | 64314250 |
Anal incontinence | 19.77 | 13.14 | 24 | 20004 | 15172 | 64463532 |
Pharyngeal mass | 19.51 | 13.14 | 6 | 20022 | 273 | 64478431 |
Spinal cord haemorrhage | 19.35 | 13.14 | 7 | 20021 | 528 | 64478176 |
Urinary tract disorder | 19.01 | 13.14 | 12 | 20016 | 3154 | 64475550 |
Cardio-respiratory arrest | 18.44 | 13.14 | 4 | 20024 | 98389 | 64380315 |
Hyperventilation | 18.44 | 13.14 | 16 | 20012 | 6824 | 64471880 |
Oesophageal dilatation | 18.31 | 13.14 | 6 | 20022 | 336 | 64478368 |
Product blister packaging issue | 18.23 | 13.14 | 5 | 20023 | 151 | 64478553 |
Neutropenia | 18.13 | 13.14 | 29 | 19999 | 239595 | 64239109 |
Insomnia | 17.98 | 13.14 | 114 | 19914 | 197722 | 64280982 |
Therapeutic product effect decreased | 17.41 | 13.14 | 7 | 20021 | 115344 | 64363360 |
Bone marrow oedema | 17.23 | 13.14 | 8 | 20020 | 1142 | 64477562 |
Contraindicated product administered | 17.19 | 13.14 | 6 | 20022 | 107823 | 64370881 |
Hip fracture | 16.56 | 13.14 | 30 | 19998 | 27069 | 64451635 |
Amnesia | 16.28 | 13.14 | 42 | 19986 | 48227 | 64430477 |
Vascular stenosis | 16.20 | 13.14 | 6 | 20022 | 484 | 64478220 |
Treatment failure | 16.20 | 13.14 | 8 | 20020 | 116808 | 64361896 |
Persistent genital arousal disorder | 16.00 | 13.14 | 5 | 20023 | 240 | 64478464 |
Dropped head syndrome | 16.00 | 13.14 | 5 | 20023 | 240 | 64478464 |
Hallucination, visual | 15.99 | 13.14 | 30 | 19998 | 27804 | 64450900 |
Maternal exposure during pregnancy | 15.87 | 13.14 | 5 | 20023 | 95879 | 64382825 |
Paraesthesia | 15.80 | 13.14 | 83 | 19945 | 134439 | 64344265 |
Hypertonic bladder | 15.79 | 13.14 | 11 | 20017 | 3407 | 64475297 |
Extradural haematoma | 15.71 | 13.14 | 10 | 20018 | 2666 | 64476038 |
Sputum retention | 15.56 | 13.14 | 7 | 20021 | 930 | 64477774 |
Perineal pain | 15.10 | 13.14 | 7 | 20021 | 996 | 64477708 |
Somatic dysfunction | 14.88 | 13.14 | 3 | 20025 | 22 | 64478682 |
Intentional medical device removal by patient | 14.85 | 13.14 | 5 | 20023 | 305 | 64478399 |
Abdominal pain upper | 14.77 | 13.14 | 99 | 19929 | 174931 | 64303773 |
Product use complaint | 14.52 | 13.14 | 8 | 20020 | 1638 | 64477066 |
Stoma site discharge | 14.36 | 13.14 | 8 | 20020 | 1674 | 64477030 |
Catheter site injury | 14.34 | 13.14 | 4 | 20024 | 129 | 64478575 |
Drug hypersensitivity | 14.31 | 13.14 | 33 | 19995 | 237782 | 64240922 |
Rheumatoid arthritis | 14.29 | 13.14 | 18 | 20010 | 164276 | 64314428 |
Feeling abnormal | 14.06 | 13.14 | 80 | 19948 | 133522 | 64345182 |
Product dose omission issue | 14.02 | 13.14 | 106 | 19922 | 194641 | 64284063 |
Atrial fibrillation | 13.97 | 13.14 | 96 | 19932 | 170993 | 64307711 |
Open fracture | 13.72 | 13.14 | 5 | 20023 | 385 | 64478319 |
Intercepted medication error | 13.69 | 13.14 | 6 | 20022 | 749 | 64477955 |
Lip swelling | 13.15 | 13.14 | 30 | 19998 | 31877 | 64446827 |
None
Source | Code | Description |
---|---|---|
ATC | G04BD12 | GENITO URINARY SYSTEM AND SEX HORMONES UROLOGICALS UROLOGICALS Drugs for urinary frequency and incontinence |
MeSH PA | D018663 | Adrenergic Agents |
MeSH PA | D000322 | Adrenergic Agonists |
MeSH PA | D058667 | Adrenergic beta-3 Receptor Agonists |
MeSH PA | D000318 | Adrenergic beta-Agonists |
MeSH PA | D018377 | Neurotransmitter Agents |
MeSH PA | D064804 | Urological Agents |
FDA MoA | N0000182137 | Cytochrome P450 2D6 Inhibitors |
FDA MoA | N0000185007 | Adrenergic beta3-Agonists |
FDA EPC | N0000185008 | beta3-Adrenergic Agonist |
FDA MoA | N0000185503 | P-Glycoprotein Inhibitors |
FDA MoA | N0000190114 | Cytochrome P450 3A Inhibitors |
CHEBI has role | CHEBI:35522 | beta-adrenergic agonists |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Bladder muscle dysfunction - overactive | indication | 236633002 | |
Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 12.32 | acidic |
pKa2 | 8.7 | Basic |
pKa3 | 4.93 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
25MG | MYRBETRIQ | APGDI | N202611 | June 28, 2012 | RX | TABLET, EXTENDED RELEASE | ORAL | 8835474 | Nov. 4, 2023 | FOR THE TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY |
25MG | MYRBETRIQ | APGDI | N202611 | June 28, 2012 | RX | TABLET, EXTENDED RELEASE | ORAL | RE44872 | Nov. 4, 2023 | FOR THE TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY |
50MG | MYRBETRIQ | APGDI | N202611 | June 28, 2012 | RX | TABLET, EXTENDED RELEASE | ORAL | 8835474 | Nov. 4, 2023 | FOR THE TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY |
50MG | MYRBETRIQ | APGDI | N202611 | June 28, 2012 | RX | TABLET, EXTENDED RELEASE | ORAL | RE44872 | Nov. 4, 2023 | FOR THE TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY |
25MG | MYRBETRIQ | APGDI | N202611 | June 28, 2012 | RX | TABLET, EXTENDED RELEASE | ORAL | 8772315 | Oct. 30, 2028 | USE IN COMBINATION WITH THE MUSCARINIC ANTAGONIST SOLIFENACIN SUCCINATE FOR THE TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY |
50MG | MYRBETRIQ | APGDI | N202611 | June 28, 2012 | RX | TABLET, EXTENDED RELEASE | ORAL | 8772315 | Oct. 30, 2028 | USE IN COMBINATION WITH THE MUSCARINIC ANTAGONIST SOLIFENACIN SUCCINATE FOR THE TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY |
25MG | MYRBETRIQ | APGDI | N202611 | June 28, 2012 | RX | TABLET, EXTENDED RELEASE | ORAL | 10842780 | Sept. 28, 2029 | ADMINISTRATION OF AN EXTENDED RELEASE TABLET FOR THE TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY |
50MG | MYRBETRIQ | APGDI | N202611 | June 28, 2012 | RX | TABLET, EXTENDED RELEASE | ORAL | 10842780 | Sept. 28, 2029 | ADMINISTRATION OF AN EXTENDED RELEASE TABLET FOR THE TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY |
8MG/ML | MYRBETRIQ GRANULES | APGDI | N213801 | March 25, 2021 | RX | FOR SUSPENSION, EXTENDED RELEASE | ORAL | 10058536 | March 31, 2036 | TREATMENT OF NEUROGENIC DETRUSOR OVERACTIVITY (NDO) IN PEDIATRIC PATIENTS AGED 3 YEARS AND OLDER BY ADMINISTRATION OF AN EXTENDED-RELEASE SUSPENSION FORMULATION OF MIRABEGRON |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
25MG | MYRBETRIQ | APGDI | N202611 | June 28, 2012 | RX | TABLET, EXTENDED RELEASE | ORAL | March 25, 2024 | TREATMENT OF NEUROGENIC DETRUSOR OVERACTIVITY (NDO) IN PEDIATRIC PATIENTS 3 YEARS AND OLDER AND WEIGHING 35 KILOGRAMS OR MORE |
50MG | MYRBETRIQ | APGDI | N202611 | June 28, 2012 | RX | TABLET, EXTENDED RELEASE | ORAL | March 25, 2024 | TREATMENT OF NEUROGENIC DETRUSOR OVERACTIVITY (NDO) IN PEDIATRIC PATIENTS 3 YEARS AND OLDER AND WEIGHING 35 KILOGRAMS OR MORE |
8MG/ML | MYRBETRIQ GRANULES | APGDI | N213801 | March 25, 2021 | RX | FOR SUSPENSION, EXTENDED RELEASE | ORAL | March 25, 2024 | NEW PRODUCT |
25MG | MYRBETRIQ | APGDI | N202611 | June 28, 2012 | RX | TABLET, EXTENDED RELEASE | ORAL | Sept. 25, 2024 | PEDIATRIC EXCLUSIVITY |
50MG | MYRBETRIQ | APGDI | N202611 | June 28, 2012 | RX | TABLET, EXTENDED RELEASE | ORAL | Sept. 25, 2024 | PEDIATRIC EXCLUSIVITY |
8MG/ML | MYRBETRIQ GRANULES | APGDI | N213801 | March 25, 2021 | RX | FOR SUSPENSION, EXTENDED RELEASE | ORAL | Sept. 25, 2024 | PEDIATRIC EXCLUSIVITY |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Beta-3 adrenergic receptor | GPCR | AGONIST | EC50 | 7.65 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE |
ID | Source |
---|---|
D09535 | KEGG_DRUG |
4031804 | VANDF |
CHEBI:65349 | CHEBI |
H6U | PDB_CHEM_ID |
CHEMBL2095212 | ChEMBL_ID |
C520025 | MESH_SUPPLEMENTAL_RECORD_UI |
7445 | IUPHAR_LIGAND_ID |
8907 | INN_ID |
DB08893 | DRUGBANK_ID |
MVR3JL3B2V | UNII |
9865528 | PUBCHEM_CID |
1300786 | RXNORM |
191568 | MMSL |
28616 | MMSL |
d07876 | MMSL |
014540 | NDDF |
703803006 | SNOMEDCT_US |
703804000 | SNOMEDCT_US |
C2983812 | UMLSCUI |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Myrbetriq | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0469-2601 | TABLET, FILM COATED, EXTENDED RELEASE | 25 mg | ORAL | NDA | 27 sections |
Myrbetriq | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0469-2601 | TABLET, FILM COATED, EXTENDED RELEASE | 25 mg | ORAL | NDA | 27 sections |
Myrbetriq | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0469-2602 | TABLET, FILM COATED, EXTENDED RELEASE | 50 mg | ORAL | NDA | 27 sections |
Myrbetriq | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0469-2602 | TABLET, FILM COATED, EXTENDED RELEASE | 50 mg | ORAL | NDA | 27 sections |
Myrbetriq | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0469-5020 | GRANULE, FOR SUSPENSION, EXTENDED RELEASE | 8 mg | ORAL | NDA | 27 sections |
Myrbetriq | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0469-5020 | GRANULE, FOR SUSPENSION, EXTENDED RELEASE | 8 mg | ORAL | NDA | 27 sections |
Myrbetriq | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55154-8712 | TABLET, FILM COATED, EXTENDED RELEASE | 25 mg | ORAL | NDA | 27 sections |
Myrbetriq | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55154-8713 | TABLET, FILM COATED, EXTENDED RELEASE | 50 mg | ORAL | NDA | 27 sections |
Myrbetriq | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70518-2435 | TABLET, FILM COATED, EXTENDED RELEASE | 50 mg | ORAL | NDA | 27 sections |
Myrbetriq | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70518-3158 | TABLET, FILM COATED, EXTENDED RELEASE | 25 mg | ORAL | NDA | 27 sections |